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N-terminal pro B-type natriuretic peptide
(NT pro-BNP) is a predictor of long-term survival
in male patients of 75 years and older with high-
grade asymptomatic internal carotid artery stenosis
Nikolaus Duschek, MD,a Edda Skrinjar, MD,a Thomas Waldhör, MD,b Christian Vutuc, MD,b
Gerhard Daniel, MD,c Wolfgang Hübl, MD,d and Afshin Assadian, MD,a Vienna, Austria
Background: Carotid endarterectomy (CEA) is commonly performed for asymptomatic high-grade internal carotid artery
(ICA) stenosis to prevent stroke. However, despite advancing age of the society, for patients older than 75 years, there is
no recommendation by the European guidelines for CEA, as this age group might not benefit from this intervention due
to a limited life expectancy.
Objective: We assessed N-terminal pro B-type natriuretic peptide (NT pro-BNP) as a predictive marker for long-term
survival in this particular patient population in order to stratify patients for an improved surgical outcome.
Methods: In a nonrandomized single-center clinical trial, we prospectively studied mortality rates of 205 consecutive
patients (80 women, 125 men; mean age, 75  10 years) with asymptomatic high-grade ICA stenosis in relation to
preoperative plasma NT pro-BNP levels. We estimated cumulative survival over 5 years by Kaplan-Meier curves and
established a proportional hazard-model by Cox regression.
Results: In male patients, higher levels of preoperative NT pro-BNP levels were associated with a significantly increased
long-term mortality. Those 75 years or older had the same survival rate as younger patients, if NT pro-BNP levels were
low, making them thus eligible for CEA.
Conclusions: The results of our study suggest that preoperative plasma levels of NT pro-BNP are a valuable tool for the
stratification of male patients. Male patients older than 75 years with low levels of NT pro-BNP should be referred for
carotid revascularization, as they will most likely enjoy the benefit of surgery. (J Vasc Surg 2011;53:1242-50.)
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pThe aim of carotid endarterectomy (CEA) is to prevent
stroke. The incidence of stroke increases gradually with
advanced age,1 and, simultaneously, older persons repre-
sent an increasing proportion of our population. Based on
three randomized controlled trials (RCTs), the Society of
Vascular Surgery (SVS) guidelines recommend CEA for all
asymptomatic patients with a moderate-to-severe carotid
stenosis (60%), as long as perioperative risk is low.2 There
is no such recommendation by the European Society of
Vascular Society (ESVS)3 for CEA for patients at age 75
years or older with high-grade stenosis of the internal
carotid artery (ICA). This is based on the results of the
Asymptomatic Carotid Surgery Trial (ACST), which has
shown no significant benefit for this age group after 5 years
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1242f follow-up.4 The reason for this is the increase in non-
troke-related deaths in this age group.1 Up to now, no
CT-based data have suggested CEA for patients older
han 75 years of age; however, few series and studies
onfirmed the safety and efficiency of this approach in
ctogenarians.5,6 Myocardial infarction is responsible for
p to 50% of perioperative deaths and causes more later
eaths than strokes do.7Our aimwas therefore to search for
tool to stratify elderly patients with high-grade asymp-
omatic ICA stenosis eligible for CEA by cardiovascular
orbidity. We measured plasma N-terminal pro B-type
atriuretic peptide (NT pro-BNP) levels, which are known
o predict postoperative outcome,8-11 of consecutive pa-
ients of all ages with asymptomatic high-grade ICA steno-
is. NT pro-BNP belongs to the group of natriuretic pep-
ides secreted from cardiomyocytes in response to atrial or
entricular wall stretch.12 They have a fundamental role in
emodeling, volume homeostasis, and the response to isch-
mia. The importance and even superiority of these pep-
ides as diagnostic tools and predictors of risk in acute
oronary syndromes and heart failure has been sufficiently
roven13 and widely acknowledged.14 Furthermore, a re-
ent meta-analysis8 showed that preoperative elevated na-
riuretic peptides also identify patients undergoing non-
ardiac surgery at high risk of cardiac and all-cause
ortality. We therefore measured NT pro-BNP levels once
reoperatively, and patients were followed over 5 years for
he occurrence of death thereafter.
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Patients. From 2003 to 2009, we prospectively stud-
ied mortality rates of 205 nonrandomized consecutive pa-
tients (80 female, 125 male; mean age, 75 years) with
asymptomatic (70%-99%) high-grade ICA stenosis in rela-
tion to plasma NT pro-BNP levels (pg/mL) obtained prior
to CEA. Recruitment lasted from January 2003 to April
2004. Patients were referred to our department by general
practitioners and other specialists. The Viennese Ethics
Commission approved the study (EC nr: 04-067-0604).
Patients who gave their written informed consent under-
went a standardized vascular screening, including a health
questionnaire and laboratory assessment. Each patient was
evaluated by a board-certified neurologist and categorized
as “asymptomatic” if the patient had no history of disabling
stroke and had been neurologically asymptomatic for at
least the past 6 months. Exclusion criteria comprised any
symptomatic ICA stenosis according to Trial of Org 10172
in Acute Stroke Treatment classification,15 a previous ipsi-
lateral CEA, an expectation of high surgical risk or any
other major life-threatening condition other than carotid
stenosis. Before discharge from the hospital, it was ensured
that each patient received best medical treatment (includ-
ing acetylsalicylic acid, beta-blockers, and statins) and a
note was sent to the patient’s physician. Surgery was stan-
dardized by performing only eversion endarterectomy
(EEA) under local anesthesia with the systemic administra-
tion of 5000 units of heparin before clamping of the carotid
arteries.
Internal carotid artery stenosis assessment. Duplex
grading of ICA stenosis was performed according to previ-
ously published criteria.16,17 Peak systolic velocities (PSV)
within the ICA of 150 to 249mm/s and the ratio of PSV of
the ICA to the common carotid artery (CCA) of 2.0 to 3.9
were quantified as 50% to 69% stenosis, and PSV within the
ICA greater than 250 mm/s, and the ratio of PSV of the
ICA andCCAof greater four were quantified as 70% to 99%
stenosis. A single board-certified medical doctor at the
Department of General and Vascular Surgery performed
ultrasound examinations in order to reduce interobserver
bias. All patients were included that were diagnosed with
asymptomatic high-grade ICA stenosis (ie, uni- or bilateral
stenosis of at least 70%).
NT pro-BNP assay. From January 2003 to April
2004, venous blood samples were taken 1 to 14 days prior
to surgery during preoperative evaluation in the depart-
ment’s outpatient clinic between 9 and 11 am. Each blood
sample was collected in a standard serum tube (10 mL),
then centrifuged, and plasma stored in aliquots at -80°C.
After recruitment of all patients, plasma samples were mea-
sured with the use of a Roche Elecsys (2010) analyzer
(Roche Diagnostics GmbH, Mannheim, Germany). The
lower limit of detection was 5 pg/mL. The coefficients of
variation for within-run and day-to-day imprecision of the
assay ranged from 1.8% to 2.9% (within a concentration
range of 175-6781 pg/mL). tOutcomes. The surgical intervention for all 205 pa-
ients consisted of an EEA under local anesthesia. Periop-
rative stroke and death rates were 0.5% and 1.5%, respec-
ively. Patients were monitored regularly for the occurrence
f death as main outcome. Classic cardiovascular risk fac-
ors (age, side of EEA, body mass index, alcohol consump-
ion, hypertension, nicotine abuse, diabetes mellitus,
bA1c, creatinine, cholesterol, high-density lipoprotein,
ow-density lipoprotein, triglycerides, uric acid, NT pro-
NP) were documented as possible covariates for the es-
ablishment of our proportional hazard model. Primary
auses of deaths of patients were categorized by the Inter-
ational Classification of Diseases, tenth revision (ICD-10,
007) code. The category “cardiac death” comprised death
ue to heart failure without specification, coronary artery
isease, hypertension, myocardial infarction. The category
other death” described death due to colon cancer, lung
ancer, prostate cancer, urinary tract cancer, cerebral dis-
ase, chronic obstructive pulmonary disease, diabetes mel-
itus, Pickwicker, pneumonia, and suffocation. “Vascular
eath” was caused by ruptured aneurysm, mesenterial in-
arction, cerebrovascular disease, and stroke. Follow-up of
atients was at 1, 3, 6, and 12 months postoperatively and
n an annual basis thereafter. Data of deceased patients
ere cross-checked with the Austrian public death registry.
Statistical analysis. For the comparison of mean/
edians of NT pro-BNP plasma levels, t tests/Mann-
hitney-U tests were applied accordingly. A proportional
azard model with major cardiovascular risk factors as
ovariates was calculated by Cox regression. In addition to
ain effects, interaction terms between NT pro-BNP, gen-
er, and age were estimated. For categorical analyses, we
sed a threshold of 455.5 (455, 455 pg/mL) for NT
ro-BNP. The threshold was calculated by estimating the
uclidic cistance based on a receiver-operator characteristic
ROC) table, thus combining maximal sensitivity and spec-
ficity. For an age-based category, we used a threshold of 75
ears (75, 75 years) in order to estimate survival in
ctogenarians and nonagenarians. Kaplan-Meier curves
ere used to estimate survival stratified by categorical age
nd NT pro-BNP and gender. All analyses were performed
ith the use of SAS software (Version 9.2; SAS Institute
nc, Cary, NC) or SPSS (version 15.0.1; SPSS Inc, Chi-
ago, Ill). A two-sided P value of less than .05 was consid-
red to indicate statistical significance.
ESULTS
Baseline characteristics stratified by gender are shown
n Table I. A Cox regression analysis was used for the
stablishment of a uni- and multivariate model in order to
ssess the relevance of major cardiovascular risk factors for
he outcome of death, as presented in Table II. Significantly
igher preoperative NT pro-BNP plasma levels in deceased
P  .001) patients were observed but only in male pa-
ients, which is illustrated in Fig 1. The primary cause of
eath was cardiogenic in 40%, vascular in 18%, and related
o other diseases in 42%. Compared with younger patients,
he share of incidence of cardiogenic death increased by 7%
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stagnated and other deaths decreased, confirming not sur-
prisingly that cardiogenic death is mainly responsible for
postoperative non-stroke-related death. At the end of the
observation period (median time of observation was 66
Table I. Baseline demographics including major cardiovas
endarterectomy for asymptomatic high-grade stenosis of th
Female
Mean
Age (years) 75
Body mass index (kg/m2) 25.29
Hypertension 79%
Nicotine abuse 36%
Diabetes mellitus 15%
HbA1c (rel. %) 5, 91
Creatinine (mg/dL) 0, 96
Cholesterol (mg/dL) 210, 76
High density lipoprotein (mg/dL) 57, 18
Low density lipoprotein (mg/dL) 124, 76
Triglycerides (mg/dL) 146, 04
Uric acid (mg/dL) 5, 49
NT pro-BNP (pg/mL) 424, 94
NT pro-BNP, N-terminal pro B-type natriuretic peptide.
Table II. Uni- and multivariate model assessing the releva
mortality by Cox regression analysis
P value
Univariate analysis
Age (years) .004
Body mass index (kg/m2) .924
Hypertension .970
Nicotine abuse .956
Diabetes mellitus .006
HbA1c (rel.%) .027
Creatinine (mg/dL) .189
Cholesterol (mg/dL) .096
High-density lipoprotein (mg/dL) .190
Low-density lipoprotein (mg/dL) .614
Triglycerides (mg/dL) .467
Uric acid (mg/dL) .387
NT pro-BNP (pg/mL) .000
Multivariate analysis
Age (years) .010
Body mass index (kg/m2) .938
Hypertension .306
Nicotine abuse .300
Diabetes mellitus .161
HbA1c (rel.%) .197
Creatinine (mg/dL) .332
Cholesterol (mg/dL) .567
High density lipoprotein (mg/dL) .885
Low density lipoprotein (mg/dL) .606
Triglycerides (mg/dL) .808
Uric acid (mg/dL) .452
NT pro-BNP (pg/mL) .002
NT pro-BNP, N-terminal pro B-type natriuretic peptide.months; 25th percentile, 62 months; 75th percentile, 69 fonths), after undergoing CEA a total of 57 (27.8%)
atients had died (12 female, 45 male). The overall survival
f all patients was 72.2% (85.0% for female, 64% for male),
s shown in Fig 2. Median time of survival was 63 months
25th percentile: 57 months; 75th percentile: 68 months);
risk factors of 205 patients undergoing carotid
ernal carotid artery
Male
P value Mean Std 
10 75 9 NS
4.1 26.5 3.31 .05
41% 84% 37% NS
48% 26% 44% NS
36% 25% 43% NS
75 6, 09 0, 88 NS
21 1, 29 0, 94 .005
21 201, 69 40, 22 NS
78 49, 48 12, 58 .0001
26 116, 63 33, 26 NS
17 169, 74 97, 31 NS
37 6, 37 1, 55 .0001
92 672, 29 1677, 46 NS
of major cardiovascular risk factors for long-term
Hazard ratio (HR)
95% confidence interval
for hazard ratio
(lower and upper bound)
1.04 1.01 1.08
1.00 0.94 1.08
0.99 0.51 1.91
1.02 0.58 1.78
2.17 1.25 3.76
1.36 1.04 1.79
1.15 0.93 1.41
0.99 0.99 1.00
0.99 0.97 1.01
1.00 0.99 1.01
1.00 1.00 1.00
1.08 0.91 1.28
1.00 1.00 1.00
1.05 1.01 1.09
1.00 0.92 1.10
0.67 0.31 1.44
1.46 0.71 3.01
1.73 0.81 3.70
1.28 0.88 1.88
0.69 0.33 1.46
0.98 0.90 1.06
1.01 0.92 1.10
1.02 0.94 1.11
1.00 0.99 1.02
1.09 0.88 1.35
1.00 1.00 1.00cular
e int
Std
0,
0,
39,
13,
35,
70,
1,
515,nceor males 61 months (25th percentile: 49 months; 75th
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Volume 53, Number 5 Duschek et al 1245percentile: 67 months) and for females 65 months (25th
percentile: 60months; 75th percentile: 69months). After 5
years (60 months), those under the age of 75 years had a
survival of 82%  4.1%, whereas those aged 75 years and
more had a survival of 71%  4.2%. At every age, male
patients suffered from a significantly higher mortality rate
than women (log rank P .01). This finding illustrates the
importance of male gender to be stratified as a high-risk
group. Since the efficiency of CEA has been proven for
patients up to the age of 74,4 our investigation focused on
patients of 75 years and older. In order to find a predictive
marker for expected survival, acknowledged major cardio-
vascular risk factors (see Table I) were compared in a
proportional hazard model by Cox regression. When the
analysis was restricted to male patients, NT pro-BNP
emerged as a significant independent risk factor with a
hazard (H) of 2.53  10e-4 per each mg/dL (95% confi-
dence interval [CI] 1.48  10e-4, 3.58  10e-4; P 
.0001). Compared withNT pro-BNP, age was insignificant
for the survival of male patients. When we analyzed male
patients of 75 years and older, smoking emerged as a
second significant risk factor for survival with a hazard ratio
Fig 1. Levels of N-terminal pro B-type natriuretic pepti
error bars represent 95% confidence interval.(HR) of 3.2 (95%CI 1.2, 8.1; P .05).When we restricted pnalysis to female gender, only age remained as a single
ignificant risk factor (P  .01), whereas NT pro-BNP
emained insignificant. This applies to all female patients as
ell as to those of 75 years and older. These results show
hat for the survival of male patients, age is not as important
s the amount of plasma NT pro-BNP.
In order to examine the utility of NT pro-BNP for the
rediction of survival of male patients of 75 years and older,
OC curves were estimated. The area under the curve
AUC) was 0.80 (95 CI% 0.69, 0.91; P .0001), as shown
n Fig 3. The AUC for age was less and insignificant (AUC
.61;P .121). Based on the ROC curve for NT pro-BNP,
cutoff value of 455.5 pg/mL was calculated, in order to
llustrate the value of NT pro-BNP as a tool for stratifica-
ion. The cutoff of 455 pg/mL for NT pro-BNP for the
ssessment of the risk of postoperative mortality showed a
ensitivity of 69% and a specificity of 88%, an accuracy of
0%, a positive predictive value of 80%, and a positive
ikelihood ratio of 5.8; thus, male patients of 75 years or
lder with NT pro-BNP values above 455 had a 5.8-fold
ncreased odds of postoperative death within 5 years.
In a proportional hazard model, this cutoff of 455
T pro-BNP) by gender and status (alive/dead); box plot,de (Ng/mL NT pro-BNP was associated with an HR of 7.1
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May 20111246 Duschek et al95% CI 3.1, 16.4; P .0001) for male patients75 years.
he combined HR for smoking and high NT pro-BNP
455 pg/mL) was 8.23 (95% CI 2.61, 25.96) after
orrection for other major cardiovascular risk factors. In
nalogy to the ROC curve, age remained insignificant in
he Cox regression. When this cutoff of 455 pg/mL NT
ro-BNP was used for the estimation of survival by Kaplan-
eier-curves, male patients 75 years with high BNP
evels had a significantly (P  .001) lower survival of 32 
.3% at 60 months and 9.6  8.1% after the end of the
bservation period (67 months). Male patients 75 years
ith low BNP levels had a survival of 82.6  5.6% at 60
onths, as shown in Fig 4. Noteworthy, male patients of
5 years and older with low preoperative NT pro-BNP
evels had even more of a significantly higher survival rate
ver 5 years than these under 75 years old (70.4% overall
urvival; high NT pro-BNP 66.7%, low NT pro-BNP
0.8%).
ISCUSSION
Today, the indication for the treatment of asymptom-
tic stenosis of the carotid artery is based on the result of
wo major trials, namely the ACST4 and the Asymptomatic
ic high-grade stenosis of the internal carotid arteryFig 3. Receiver-operator characteristic (ROC) curve illustrating the
superiority of N-terminal pro B-type natriuretic peptide (NT pro-Fig 2. Survival function for all patients with asymptomat
(ICA), stratified by gender.arotid Atherosclerosis Study.18 These two trials clearly
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ment compared with deferred intervention with medical
treatment alone in patients with a moderate-to-severe ste-
nosis of the internal carotid artery. The ACST showed no
net benefit for patients over 75 years after 5 years of
follow-up.4 Patients of advanced age who are likely to die
from a non-stroke-related disease are therefore not recom-
mended to undergo surgery. Nevertheless, the proportion
of old people is continuously growing. Although there is
increasing evidence that the risk of stroke with medical
treatment alone in patients with an asymptomatic carotid
stenosis has fallen in recent years,19 the incidence of stroke
is still substantially higher in older people.1 Also, it is
noteworthy that the ACST already compared CEA and best
medical management with best medical management
alone, including acetylsalicylic acid, statins and other drugs.
Recently, 10-year follow-up data from the ACST were
presented.20 Still, there was no significant change in the
previously published estimates of the absolute risk reduc-
tion for any stroke or operative death with surgery com-
pared with best medical treatment alone (absolute risk
reduction  3.9% at 5 years and 4.3% at 10 years). Addi-
tionally, many patients do not stick to their regimen, and
the reasons for this are numerous, making it thus difficult to
improve treatment adherence.21-23 Therefore, it is neces-
sary to identify those who will still benefit from the surgical
intervention despite advanced age.
Clinical cardiovascular risk indexes have only modest
Fig 4. Survival function for all patients stratified by a
N-terminal pro B-type natriuretic peptide (NT pro-BNPpredictive power in patients undergoing noncardiac major purgery.24 Consequently, additional information for preop-
rative risk stratification is required. Noninvasive cardiac
esting like echocardiography and the dipyridamole stress
erfusion test might provide some of this information but is
xpensive and time-consuming compared with a single
reoperative blood sample of NT pro-BNP. Yun et al25
ound that although all their patients had normal left ven-
ricular function, those with perioperative complications
ad a large left atrium and high BNP level. Reasonably,
hey remarked that BNP is not only increased in heart
ailure but in other systemic diseases too.26 Actually, these
iseases are risk factors for postsurgical complications, too,
nd some of these cardiac risk factors as well.
Natriuretic peptides (NP) are secreted from cardiomy-
cytes in response to atrial or ventricular wall stretch12; the
P have a fundamental role in remodeling, volume homeo-
tasis, and the response to ischemia. The importance and
ven superiority of these peptides as diagnostic tools and
redictors of risk in acute coronary syndromes and heart
ailure has been sufficiently proven13 and widely acknowl-
dged.27 Due to its origin from the heart, BNP and NT
ro-BNP are highly specific for alterations of the cardiovas-
ular system. Pro-BNP is synthesized by myocytes and
broblasts in the atria and ventricles in response to left
entricular filling pressures and wall stress. This prohor-
one is subsequently cleaved into the 32 amino acid pep-
ide BNP and the 76 amino acid amino-terminal fragment,
T-pro BNP by the myocyte. Today, the role of these two
, 75 years), gender, and a cutoff of 455.5 pg/mL
, Internal carotid artery.ge (eptides has been evaluated in the setting of nearly every
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medical efforts, the use of NP as a predictor of adverse
events can be extended tomany other fields (eg, orthopedic
surgery).28 Beyond that, other NP have been discovered
and are actually objects of extensive investigation. For
example, C-type NP is expressed in the brain where it is
held responsible for the regulation of key axonal processes
during development.29 For cardiovascular medicine, it
seems that one of the most promising areas worth investi-
gating is the idea of an NT pro-BNP-based therapy of heart
failure, a topic that has been excellently analyzed and
published this year by O’Donoghue et al.14
Due to the impact of cardiogenic death for periopera-
tive and late mortality in patients that have undergone
CEA,7 we assessed the predictive value of NT pro-BNP to
improve long-term benefits for patients. A recent meta-
analysis by Ryding et al8 showed that preoperative elevated
NP identifies patients undergoing noncardiac surgery at
high risk of cardiac and all-cause mortality. For this meta-
analysis, 1,142 papers were reviewed, and 15 papers dealing
with prospective trials were included. Four investigated
long-term mortality, but none of these papers presented an
observation period of 5 years, nor did any address the topic
of CEA for patients over 75 years. The work of Mahla et
al30 together with the results of Feringa et al31 are the only
ones assessing NT pro-BNP as a predictor for long-term
survival in patients undergoing vascular surgery. Two other
articles assessed BNP, which is similar in its predictive value
toNT pro-BNP but has a shorter half-life and thus a greater
variability. NT pro-BNP is rather influenced by renal im-
pairment; that is why we included creatinine in our propor-
tional hazard model.
Feringa et al31 assessed a postoperative time span of 6
months in patients undergoing major vascular surgery.
Mahla et al30 evaluated NT pro-BNP over a median of 826
days (around 2 years and 3months); both results are invalid
for the assessment of long-term survival and offer no solu-
tion for the prediction of benefit of CEA in older patients.
Furthermore, both authors assess NT pro-BNP in vas-
cular surgery, mainly comprising the repair of abdominal
aortic aneurysm or infrainguinal disease, which implies a far
greater stress on the heart than the clamping of the com-
mon carotid artery during CEA, a potential bias for the
evaluation of postoperative survival rates.
In addition, a major point of investigation of Mahla et
al30 is the assessment of postoperative NT pro-BNP levels,
which may provide additional important prognostic infor-
mation to preoperative levels; postoperative levels are prob-
ably different in patients undergoing CEA than in those
undergoing abdominal aortic aneurysm repair. For our
outcome of presurgical patient stratification of patients over
75 years, only preoperative levels are useful.
Even when we corrected for the acknowledged major
cardiovascular risk factors and factors affecting NP levels,
like renal dysfunction or obesity, plasma NT pro-BNP
emerged as a highly predictive independent variable of
survival for male patients. The results of our study are clearly
limited by small numbers, thus making the calculation – fespite statistical significance  of the AUC for NT pro-
NP and age a reasonable subject for future larger trials.
evertheless, our results are the first to illustrate the poten-
ial utility of NT pro-BNP levels for the stratification of
ale asymptomatic patients 75 years for CEA.
Furthermore, it is a clear strength of our study that all
ur patients with uni- or bilateral high-grade carotid steno-
is had no cardiac history so far; thus, they were treated as
symptomatic patients with a low surgical risk, eligible for
EA. In the literature, a clear cutoff value8 or target level14
or NT pro-BNP has never been described, which is due to
he continuous rather than dichotomous character of NT
ro-BNP as a biological marker. Thus, the establishment of
uch a cutoff will always vary within individual patient
roups. Even so, the recommendation for carotid surgery
s, too, based on statistical calculations and cutoffs, like the
ge of 75 according to the ACST.4 Therefore, the inclusion
f an additional, yet more powerful marker than age would
efinitely add to the net benefit of this intervention.
Our results show no predictive value of NT pro-BNP in
lderly female patients and female patients with ICA steno-
is in general. Compared withmale patients, female patients
ad lower mean (total 424.9 pg/mL NT pro-BNP; alive
31.5, deceased 387.7) and higher median levels (267.9
g/mL NT pro-BNP; alive 261.6, deceased 287.9), as
hown in Fig 1. Furthermore, NT pro-BNP levels were not
ignificantly elevated in female patients that died during the
ollow-up. Our Kaplan-Meier estimates even showed that
emale patients with higher NT pro-BNP levels had an
nsignificant but higher survival rate. Due to our small
emale sample size with large standard deviations, a type II
rror might be present. The lack of association of NT
ro-BNP and women as compared with men is a very
mportant field of investigation, as this points to a poten-
ially diverse role of NT pro-BNP in the pathophysiology of
arotid artery stenosis. Even so, in the literature, the pres-
nce of higher levels of BNP in women and older persons
ithout cardiovascular disease has been reported.32-34 This
ssociation of female gender and elevated BNP levels ap-
eared to be related to estrogen status, as BNP levels were
igher in women using hormone replacement therapy.32
imilar results were obtained in patients with congestive
eart failure (CHF).35 Women are less frequently affected
y carotid artery stenosis (CAS). This is supposedly caused
y a protective effect of estrogens, which should conse-
uently lead to higher BNP levels in these patients as well.
n the other hand, the pathophysiology of CHF and CAS
s completely different.
Noteworthy, diverse BNP and NT pro-BNP levels
ithin various entities of cardiac disease have been al-
eady described by Wang et al.13 Although they found an
ncreased risk of heart failure, atrial fibrillation, and
ransient ischemic attack associated with elevated BNP
evels, they failed to show this in coronary artery dis-
ase.13
Therefore, we come to the conclusion that higher levels
f NT pro-BNP in healthy women and those with heart
ailure might not be detected in female patients with CAS.
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Rutten et al,36 who described arterial stiffness as a determi-
nant of increased NP levels in individuals without cardio-
vascular disease. The authors summarized that, compared
with men, the association between NT pro-BNP and carotid-
femoral pulse wave velocity (cfPWV), a widely adopted
parameter for arterial stiffening as a manifestation of ath-
erosclerosis, was not significant after multivariable adjust-
ment in women. They hold their findings to be rather valid
in older individuals without cardiovascular disease and to
be gender-specific, because it was less pronounced in
women. Similar to our results, age emerged as an important
confounder of the association between arterial stiffness and
NT pro-BNP.36 In a sample of the Framingham cohort,
Levy et al even found an inverse relationship between BNP
and cfPWV in female patients with increased arterial stiff-
ness.37
NT pro-BNP is believed to be a surrogate marker of
the degree of cardiovascular disease. Even if NT pro-
BNP is reduced by appropriate cardiac medication, the
long-standing damage of the cardiovascular system37
indicated by chronically elevated NT pro-BNP levels
cannot be undone. This is why men older than 75 years
might not benefit from a NT pro-BNP-based therapy,14
which makes NT pro-BNP a very reliable tool for strati-
fication in this patient cohort.
CONCLUSIONS
While the ESVS guidelines limit the recommendation
for CEA to patients 75 years, the SVS guidelines suggest
CEA for any patient with moderate-to-severe stenosis, as
long as perioperative risk is acceptable. We believe that
measurement of preoperative NT pro-BNP levels is a valu-
able tool to stratify male patients of 75 years and older that
bear a low risk of adverse outcomes after surgery. Their
long-term survival rates would not be less than those from
younger patients, thus justifying CEA in this population
and allowing them to benefit from this operation.
The authors would like to thank Dr Georg Wicken-
hauser for his performance of carotid ultrasonography for
ICA stenosis assessment.
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